Dr. Gomella Discusses Interdisiplinary Treatment

Leonard G. Gomella, MD from the Jefferson Kimmel Cancer Center Discusses Interdisiplinary Treatment

Related Videos
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Evan Y. Yu, MD, professor, medical oncology, assistant fellowship director, University of Washington School of Medicine, professor, Clinical Research Division, clinical research director, Genitourinary Medical Oncology, Fred Hutchinson Cancer Center, medical director, clinical research support, Fred Hutchinson Cancer Research Consortium
Michael A. Carducci, MD, professor of oncology, AEGON Professor of Prostate Cancer Research, Johns Hopkins Medicine
Michael S. Cookson, MD, MMHC, professor, chairman of urology, University of Oklahoma College of Medicine, chief, Urology, Stephenson Cancer Center
Andrei H. Iagaru, MD, professor of Radiology - Nuclear Medicine, chief, Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center
Jeremie Calais, MD, MSc, assistant professor of nuclear medicine and theranostics, David Geffen School of Medicine, University of California, Los Angeles (UCLA), UCLA Health,
Tanya Dorff, MD, medical oncologist, associate clinical professor, Department of Medical Oncology & Therapeutics Research, City of Hope
Matthew Rettig, MD, chief, hematology-oncology, VA Medical Center, professor of medicine and urology, David Geffen School of Medicine, University of California, Los Angeles (UCLA) Health
Tian Zhang, MD, MHS
Maha H. Hussain, MD, FASCO, FACP, Genevieve E. Teuton professor of medicine, Division of Hematology Oncology, Department of Medicine, deputy director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
Related Content

Enzalutamide Plus Leuprolide Improves MFS in Nonmetastatic Castration-Sensitive Prostate Cancer

March 17th 2023

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22nd 2022

BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors

March 15th 2023

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 15th 2022

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Enzalutamide Plus Leuprolide Improves MFS in Nonmetastatic Castration-Sensitive Prostate Cancer

March 17th 2023

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22nd 2022

BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors

March 15th 2023

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 15th 2022

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Enzalutamide Plus Leuprolide Improves MFS in Nonmetastatic Castration-Sensitive Prostate Cancer

March 17th 2023

Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

August 22nd 2022

BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors

March 15th 2023

FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 15th 2022

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023